IM Cannabis (IMCC) Competitors $2.62 -0.02 (-0.76%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. VOR, PASG, DARE, CVKD, GBIO, CYCC, IPA, GDTC, EGRX, and TPSTShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Vor Biopharma (VOR), Passage Bio (PASG), Daré Bioscience (DARE), Cadrenal Therapeutics (CVKD), Generation Bio (GBIO), Cyclacel Pharmaceuticals (CYCC), ImmunoPrecise Antibodies (IPA), CytoMed Therapeutics (GDTC), Eagle Pharmaceuticals (EGRX), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors Vor Biopharma Passage Bio Daré Bioscience Cadrenal Therapeutics Generation Bio Cyclacel Pharmaceuticals ImmunoPrecise Antibodies CytoMed Therapeutics Eagle Pharmaceuticals Tempest Therapeutics Vor Biopharma (NYSE:VOR) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Does the media favor VOR or IMCC? In the previous week, IM Cannabis had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 2 mentions for IM Cannabis and 1 mentions for Vor Biopharma. IM Cannabis' average media sentiment score of 0.43 beat Vor Biopharma's score of -1.00 indicating that IM Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Vor Biopharma Negative IM Cannabis Neutral Which has preferable earnings and valuation, VOR or IMCC? Vor Biopharma has higher earnings, but lower revenue than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.51-0.14IM Cannabis$54.47M0.11-$7.04M-$0.64-4.09 Which has more volatility & risk, VOR or IMCC? Vor Biopharma has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Is VOR or IMCC more profitable? Vor Biopharma has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. Vor Biopharma's return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A IM Cannabis -25.55%-129.86%-23.63% Do analysts recommend VOR or IMCC? Vor Biopharma presently has a consensus target price of $7.06, suggesting a potential upside of 3,309.25%. Given Vor Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.40IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of VOR or IMCC? 97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 2.9% of Vor Biopharma shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in VOR or IMCC? Vor Biopharma received 50 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 65.88% of users gave Vor Biopharma an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformVor BiopharmaOutperform Votes5665.88% Underperform Votes2934.12% IM CannabisOutperform Votes642.86% Underperform Votes857.14% SummaryVor Biopharma beats IM Cannabis on 10 of the 16 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.85M$1.20B$5.61B$8.62BDividend YieldN/AN/A5.28%4.17%P/E Ratio-0.7712.4827.1419.96Price / Sales0.1111.16411.83157.63Price / CashN/A10.4038.2534.64Price / Book0.581.497.064.69Net Income-$7.04M-$56.07M$3.23B$248.14M7 Day Performance-8.07%2.01%2.67%2.39%1 Month Performance62.63%0.70%8.82%6.05%1 Year Performance-8.40%-31.51%31.44%13.60% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.4222 of 5 stars$2.62-0.8%N/A-9.9%$5.85M$54.47M-0.77340Short Interest ↑VORVor Biopharma2.5841 of 5 stars$0.23-3.7%$7.06+3,026.8%-82.4%$28.20MN/A-0.14140Short Interest ↑PASGPassage Bio2.9604 of 5 stars$0.45+2.8%$7.50+1,571.9%-57.9%$27.88MN/A-0.38130Positive NewsGap UpDAREDaré Bioscience1.733 of 5 stars$3.06+1.0%$12.00+292.2%-41.6%$27.08M$25.91K-5.1830Analyst RevisionCVKDCadrenal Therapeutics3.5154 of 5 stars$13.45-0.7%$32.00+137.9%N/A$26.46MN/A-2.014News CoveragePositive NewsShort Interest ↓Gap UpGBIOGeneration Bio4.0988 of 5 stars$0.39+2.5%$7.33+1,761.3%-87.5%$26.41M$24.56M-0.18150Positive NewsShort Interest ↓CYCCCyclacel Pharmaceuticals1.1611 of 5 stars$1.68+2.4%N/A-98.9%$25.87M$14K-0.1814IPAImmunoPrecise Antibodies2.6639 of 5 stars$0.56-1.8%$4.00+613.0%-41.1%$25.67M$24.00M-0.7280News CoverageOptions VolumeGDTCCytoMed Therapeutics2.6181 of 5 stars$2.35+1.1%$5.00+113.2%+2.9%$25.65M$69.50K0.00N/APositive NewsGap UpEGRXEagle PharmaceuticalsN/A$1.98-1.3%N/A-37.5%$25.65M$257.55M0.00100Gap DownTPSTTempest Therapeutics2.5562 of 5 stars$6.82+1.8%$30.00+339.9%-81.5%$25.11MN/A-4.4620News CoverageGap Up Related Companies and Tools Related Companies VOR Competitors PASG Competitors DARE Competitors CVKD Competitors GBIO Competitors CYCC Competitors IPA Competitors GDTC Competitors EGRX Competitors TPST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMCC Stock Free IMCC Stock Alerts